These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29521573)

  • 1. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Buck D; Andlauer TF; Igl W; Wicklein EM; Mühlau M; Weber F; Köchert K; Pohl C; Arnason B; Comi G; Cook S; Filippi M; Hartung HP; Jeffery D; Kappos L; Barkhof F; Edan G; Freedman MS; Montalbán X; Müller-Myhsok B; Hemmer B;
    Mult Scler; 2019 Apr; 25(4):565-573. PubMed ID: 29521573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
    Núñez C; Cénit MC; Alvarez-Lafuente R; Río J; Fernández-Arquero M; Arroyo R; Montalbán X; Fernández O; Oliver-Martos B; Leyva L; Comabella M; Urcelay E
    J Med Genet; 2014 Jun; 51(6):395-400. PubMed ID: 24748646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
    Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
    PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
    Weber F; Cepok S; Wolf C; Berthele A; Uhr M; Bettecken T; Buck D; Hartung HP; Holsboer F; Müller-Myhsok B; Hemmer B
    Pharmacogenomics J; 2012 Jun; 12(3):238-45. PubMed ID: 21502966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients.
    Enevold C; Oturai AB; Sørensen PS; Ryder LP; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2010 Aug; 16(8):942-9. PubMed ID: 20595247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.
    Samadzadeh S; Tabibian E; Sabokbar T; Shakoori A; Dehgolan SR; Armaki SA; Aslanbeigi B; Abolfazli R
    J Neurol Sci; 2015 May; 352(1-2):37-40. PubMed ID: 25824849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis.
    Dunn N; Fogdell-Hahn A; Hillert J; Spelman T
    Front Immunol; 2020; 11():583560. PubMed ID: 33178215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.
    Hoffmann S; Cepok S; Grummel V; Lehmann-Horn K; Hackermüller J; Stadler PF; Hartung HP; Berthele A; Deisenhammer F; Wassmuth R; Hemmer B
    Am J Hum Genet; 2008 Aug; 83(2):219-27. PubMed ID: 18656179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta.
    Lundkvist M; Greiner E; Hillert J; Fogdell-Hahn A
    Mult Scler; 2010 Jul; 16(7):796-800. PubMed ID: 20534645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of HLA DRB1 alleles with IgG oligoclonal bands and their influence on multiple sclerosis course and disability status.
    Balnytė R; Rastenytė D; Vaitkus A; Skrodenienė E; Vitkauskienė A; Ulozienė I
    Medicina (Kaunas); 2016; 52(4):217-222. PubMed ID: 27515835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P; Alm GV; Fredrikson S; Link H
    Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
    Petersen ER; Søndergaard HB; Laursen JH; Olsson AG; Börnsen L; Soelberg Sørensen P; Sellebjerg F; Bang Oturai A
    Mult Scler; 2019 Aug; 25(9):1298-1305. PubMed ID: 30070595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.
    Wencel-Warot A; Michalak S; Warot M; Kalinowska-Lyszczarz A; Kazmierski R
    Medicine (Baltimore); 2016 Nov; 95(45):e5337. PubMed ID: 27828855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.
    Mazdeh M; Taheri M; Sayad A; Bahram S; Omrani MD; Movafagh A; Inoko H; Akbari MT; Noroozi R; Hajilooi M; Solgi G
    Pharmacogenomics; 2016 Apr; 17(5):489-98. PubMed ID: 27020477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.
    Durelli L; Barbero P; Cucci A; Ferrero B; Ricci A; Contessa G; De Mercanti S; Ripellino P; Lapuma D; Viglietta E; Bergui M; Versino E; Clerico M;
    Expert Opin Biol Ther; 2009 Apr; 9(4):387-97. PubMed ID: 19278300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.